M&A Deal Summary |
|
---|---|
Date | 2008-01-22 |
Target | Hologic - Gestiva |
Sector | Life Science |
Buyer(s) | KV Pharmaceutical |
Sellers(s) | Hologic |
Deal Type | Divestiture |
Deal Value | 82M USD |
SEARCH BY
Try For Free 7-Day Free Trial
KV Pharmaceutical Co. engages in development, manufacturer, acquires and markets branded and generic/non-branded prescription pharmaceutical products.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2008) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2009-09-21 |
KV Pharmaceutical - ANDA
Chesterfield, Missouri, United States KV Pharmaceutical - ANDA comprises clindamycin phosphate (1%) and benzoyl peroxide (5%) gel. Duac gel, indicated for the topical treatment of inflammatory acne vulgaris. |
Sell | $14M |
Category | Company |
---|---|
Founded | 1985 |
Sector | Medical Products |
Employees | 6,944 |
Revenue | 4.0B USD (2023) |
Hologic is a developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products, with an emphasis on serving the healthcare needs of women throughout the world. Hologic was formed in 1985 and is based in Marlborough, Massachusetts.
DEAL STATS | # |
---|---|
Overall | 1 of 4 |
Sector (Life Science) | 1 of 2 |
Type (Divestiture) | 1 of 4 |
Country (United States) | 1 of 4 |
Year (2008) | 1 of 1 |
Size (of disclosed) | 3 of 3 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2007-10-22 |
Cytyc
Marlborough, Massachusetts, United States Cytyc Corp, is a design, development, manufacture, and marketing of clinical products that focus on women’s health. |
Buy | $6.2B |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2008-06-09 |
Third Wave Technologies
Madison, Wisconsin, United States Third Wave Technologies, Inc. is a developer and marketer of molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader chemistry. The company's current clinical diagnostic offerings consist of products for conditions such as Cystic Fibrosis, Hepatitis C, cardiovascular risk and other diseases. |
Buy | $580M |